NCT06593548
Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal Cancer
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
PFS
Timeframe: The time from the start of treatment until disease progression (PD) or death from any cause,whichever came first, assessed up to 100 months
Arms and interventions
AK112 combined with CapeOX and radiotherapyExperimental
Participants will receive Ivosidenib in combination with CapeOX chemotherapy and radiotherapy. Participants will first receive Ivosidenib in combination with CapeOX during the first cycle, followed by radiotherapy starting 2 weeks after medication.
Drugs: Ivosidenib (AK112)
Sites
1 site in 1 country
- Xinxiang LiShanghai, Shanghai Municipality, China